FEATURES OF ARCHITECTONICS OF NEOPLASMS AND MOLECULAR PROFILE OF TUMOR CELLS IN PATIENTS WITH BREAST CANCER
Keywords:
breast cancer, invasive component, intratumoral heterogeneity, parenchymal-stromal ratios, epithelial spatial structures, Кі-67, ER, E-cadherin, lactoferrin.Abstract
Summary. Expansion of possibilities for an objective assessment of the invasive potential of primary cancer cells
(CC) in breast cancer (BC) patients process is one of the
primary tasks of clinical oncology for personalized prognosis of cancer course. Objective: to study the features of
the architectonics of the primary CC obtained from tumors
of patients with invasive ductal BC, taking into account
parenchymal-stromal ratios and the organization of spatial structures of the invasive component, and to compare
the expressions of tumor lactoferrin (LF) and other markers of biological activity of tumors, in particular the antigen of proliferation of Ki-67, estrogen receptor (ER) and
E-cadherin adhesion marker in CC. Object and methods: the study was conducted on the clinical material from
116 patients with BC (T2N0M0–T2N1M0; stage II)
with a verified pathomorphological diagnosis — invasive
ductal cancer, G2. In 17 patients, metastases were detected in one and more regionar lymph nodes. Immunohistochemical studies of LF expression and markers of biological activity of tumors (Ki-67, ER, E-cadherin) were
performed using monoclonal antibodies specific to the indicated markers, keeping the algorithm and the requirements provided for such studies. Results: within the one
histological form of BC— invasive ductal cancer, in addition to heterogeneity of the general structure of the tumor,
as well as intracellular cell diversity of their cytoarchitectonics, heterogeneity of the molecular profile of tumors was
determined according to the expression of tumor biological
activity markers (Ki-67, ER, E-cadherin), which is associated with various manifestations of LF expression in
tumor cells, which, according to the literature, has modulatory properties. Conclusions: the obtained data are a
fundamental basis for the use of morphological characteristics of the invasive component of the primary cells of
the invasive ductal BC in conjunction with the parameters of the molecular profile: expression of LF, Ki-67, ER,
and E-cadherin, as objective factors for the personalized
forecast of the course of tumor the process.
References
World Health Organization (WHO) (http://www.who.int/cancer/).
Makki J. Diversity of breast carcinoma: histological subtypes and clinical relevance. Clin Med Insights Pathol 2015; 8: 23–31.
Beca F, Polyak K. Intratumor heterogeneity in breast cancer. Adv Exp Med Biol 2016; 882: 169–89.
Roulot A, Héquet D, Guinebretière JM, et al. Tumoral heterogeneity of breast cancer. Ann Biol Clin (Paris) 2016; 74 (6):
–60.
Bondarenko IN, Elhajj MH, Prokhach AV, et al. Breast cancer. From molecular biology to personified therapy. Morphologia 2016; 10 (1): 18–25 (in Russian).
Ryška A. Molecular pathology in real time. Cancer Metastasis Rev 2016; 35 (1): 129–40.
Brabrand A, Kariuki II, Engstrøm MJ, et al. Alterations in collagen fibre patterns in breast cancer. A premise for tumour invasiveness? APMIS 2015; 123 (1): 1–8.
Gerashchenko TS, Zavyalova MV, Denisov EB, et al. Intratumor morphological heterogeneity of invasive breast cancer: formation and molecular genetic features. Med Academic Journal 2012; 12 (4): 668 (in Russian).
Wang K, He J, Wang H, et al. Prognostic value of poorly differentiated clusters in invasive breast cancer. World J Surg Oncol 2014; 12: 310.
Zavyalova MV, Denisov EV, Tashireva L, et al. Phenotypic drift as a cause for intratumoral morphological heterogeneity of invasive ductal breast carcinoma not otherwise specified. BioResearch open access 2013; 2 (2): 148–54.
Hofmeyer S, Pekár G, Gere M, et al. Comparison of the subgross distribution of the lesions in invasive ductal and lobular carcinomas of the breast: a large-format histology study. International Journal of Breast Cancer 2012; 2012 (2012): 7 p.
Martelotto LG, Ng CK, Piscuoglio S, et al. Breast cancer intra-tumor heterogeneity. Breast Cancer Res 2014; 16 (3): 210.
Esparza-López J, Escobar-Arriaga E, Soto-Germes S, Ibarra-Sánchez MJ. Breast cancer intra-tumor heterogeneity:
one tumor, different entities. Rev Invest Clin 2017; 69 (2): 66–76.
Koren S, Bentires-Alj M. Breast tumor heterogeneity: source of fitness, hurdle for therapy.Mol Cell 2015; 60 (4): 537–46.
Aleskandarany MA, Vandenberghe ME, Marchiò C, et al. Tumour heterogeneity of breast cancer: from morphology to personalised medicine. Pathobiology 2018; 85 (1–2): 23–34.
Gerashchenko TS, Denisov EV, Litviakov NV, et al.Intratumoral heterogeneity: nature and biological significance. Biochemistry 2013; 78 (11): 1531–49 (in Russian).
Denisov EV, Gerashchenko TS, Tashireva LA, et al. The significance of intratumor morphological heterogeneity in breast cancer progression and pathogenetic mechanisms. Ann Oncol
; 26 (9): 153–5.
Krakhmal NV, Zavyalova MV, Denisov EV, et al. Cancer invasion: patterns and mechanisms. Acta Naturae 2015; 7 (2): 17–28.
Chekhun SV, Lukyanova NY, Sobchenko SO, et al. The relationship of serum and tumor ferritin levels with clinico-morphological characteristics and molecular subtype of tumors in patients with breast cancer. Oncologia 2014; 16 (4): 275–82 (in Ukrainian).
Chekhun VF, Yalovenko TN, Pavlova AA, Lukianova NU. The clinical significance of the level of metal-containing proteins in the blood serum of patients with breast cancer. Oncological Journal 2016; 10 (2): 7–13 (in Russian).
Hwang SM, Chung IY, Jo JH, et al. Comparison of proliferative effect of human lactoferrin and its proteolytic peptide on normal and transformed epithelial cells. Appl Biochem Biotechnol 2016; 178 (1): 44–57.
Škovierová H, Okajčeková T, Strnádel J, et al. Molecular regulation of epithelial-to-mesenchymal transition in tumorigenesis. Int J Mol Med 2018; 41 (3): 1187–200.
Gerashchenko TS, Zavyalova MV, Denisov EV, et al.Intratumoral morphological heterogeneity of breast cancer as an indicator of the metastatic potential and tumor chemosensitivity. Acta Naturae 2017; 9 (1): 56–67.
Naleskina LA, Lukianova NY, Sobchenko SO, et al.Lactoferrin expression in breast cancer in relation to biologic properties of tumors and clinical features of disease. Exp Oncol 2016; 38 (3): 181–6.
Conklin MW, Keely PJ. Why the stroma matters in breast cancer: insights into breast cancer patient outcomes through the examination of stromal biomarkers. Cell Adh Migr 2012; 6 (3): 249–60.
Krakhmal NV, Zavyalova MV, Perelmuter VM, et al. Heterogenenous expression of markers associated with invasive breast cancer. Siberian Journal of Oncology 2016; 15 (4): 56–61 (in Russian).
